Q1 Not Super Important for Johnson & Johnson (JNJ), But New Products Are - UBS
Tweet Send to a Friend
Johnson & Johnson (NYSE: JNJ) finished 1.5 percent higher Tuesday after UBS raised its price target on the drug giant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
